Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database

Mika Junnila, Inari Laaksonen, Antti Eskelinen, Pekka Pulkkinen, Leif Ivar Havelin, Ove Furnes, Anne Marie Fenstad, Alma B Pedersen, Søren Overgaard, Johan Kärrholm, Göran Garellick, Henrik Malchau, Keijo T Mäkelä

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

98 Downloads (Pure)

Resumé

Background and purpose - According to previous Nordic Arthroplasty Register Association (NARA) data, the 10-year implant survival of cemented total hip arthroplasties (THAs) is 94% in patients aged 65-74 and 96% in patients aged 75 or more. Here we report a brand-level comparison of cemented THA based on the NARA database, which has not been done previously. Patients and methods - We determined the rate of implant survival of the 9 most common cemented THAs in the NARA database. We used Kaplan-Meier analysis with 95% CI to study implant survival at 10 and 15 years, and Cox multiple regression to assess survival and hazard ratios (HRs), with revision for any reason as endpoint and with adjustment for age, sex, diagnosis, and femoral head material. Results - Spectron EF THA (89.9% (CI: 89.3-90.5)) and Elite THA (89.8% (CI: 89.0-90.6)) had the lowest 10-year survivorship. Lubinus (95.7% survival, CI: 95.5-95.9), MS 30 (96.6%, CI: 95.8-97.4), and C-stem THA (95.8%, CI: 94.8-96.8) had a 10-year survivorship of at least 95%. Lubinus (revision risk (RR) = 0.77, CI: 0.73-0.81), Müller (RR =0.83, CI: 0.70-0.99), MS-30 (RR =0.73, CI: 0.63-0.86), C-stem (RR =0.70, CI: 0.55-0.90), and Exeter Duration THA (RR =0.84, CI: 0.77-0.90) had a lower risk of revision than Charnley THA, the reference implant. Interpretation - The Spectron EF THA and the Elite THA had a lower implant survival than the Charnley, Exeter, and Lubinus THAs. Implant survival of the Müller, MS 30, CPT, and C-stem THAs was above the acceptable limit for 10-year survival.

OriginalsprogEngelsk
TidsskriftActa Orthopaedica
Vol/bind87
Udgave nummer6
Sider (fra-til)546-553
ISSN1745-3674
DOI
StatusUdgivet - dec. 2016

Fingeraftryk

Hip
Databases
Equipment and Supplies
Survival Rate

Citer dette

Junnila, M., Laaksonen, I., Eskelinen, A., Pulkkinen, P., Ivar Havelin, L., Furnes, O., ... Mäkelä, K. T. (2016). Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database. Acta Orthopaedica, 87(6), 546-553. https://doi.org/10.1080/17453674.2016.1222804
Junnila, Mika ; Laaksonen, Inari ; Eskelinen, Antti ; Pulkkinen, Pekka ; Ivar Havelin, Leif ; Furnes, Ove ; Marie Fenstad, Anne ; Pedersen, Alma B ; Overgaard, Søren ; Kärrholm, Johan ; Garellick, Göran ; Malchau, Henrik ; Mäkelä, Keijo T. / Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database. I: Acta Orthopaedica. 2016 ; Bind 87, Nr. 6. s. 546-553.
@article{5faaa20f9f2c4efd9a85ce0bc167b2f0,
title = "Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database",
abstract = "Background and purpose - According to previous Nordic Arthroplasty Register Association (NARA) data, the 10-year implant survival of cemented total hip arthroplasties (THAs) is 94{\%} in patients aged 65-74 and 96{\%} in patients aged 75 or more. Here we report a brand-level comparison of cemented THA based on the NARA database, which has not been done previously. Patients and methods - We determined the rate of implant survival of the 9 most common cemented THAs in the NARA database. We used Kaplan-Meier analysis with 95{\%} CI to study implant survival at 10 and 15 years, and Cox multiple regression to assess survival and hazard ratios (HRs), with revision for any reason as endpoint and with adjustment for age, sex, diagnosis, and femoral head material. Results - Spectron EF THA (89.9{\%} (CI: 89.3-90.5)) and Elite THA (89.8{\%} (CI: 89.0-90.6)) had the lowest 10-year survivorship. Lubinus (95.7{\%} survival, CI: 95.5-95.9), MS 30 (96.6{\%}, CI: 95.8-97.4), and C-stem THA (95.8{\%}, CI: 94.8-96.8) had a 10-year survivorship of at least 95{\%}. Lubinus (revision risk (RR) = 0.77, CI: 0.73-0.81), M{\"u}ller (RR =0.83, CI: 0.70-0.99), MS-30 (RR =0.73, CI: 0.63-0.86), C-stem (RR =0.70, CI: 0.55-0.90), and Exeter Duration THA (RR =0.84, CI: 0.77-0.90) had a lower risk of revision than Charnley THA, the reference implant. Interpretation - The Spectron EF THA and the Elite THA had a lower implant survival than the Charnley, Exeter, and Lubinus THAs. Implant survival of the M{\"u}ller, MS 30, CPT, and C-stem THAs was above the acceptable limit for 10-year survival.",
author = "Mika Junnila and Inari Laaksonen and Antti Eskelinen and Pekka Pulkkinen and {Ivar Havelin}, Leif and Ove Furnes and {Marie Fenstad}, Anne and Pedersen, {Alma B} and S{\o}ren Overgaard and Johan K{\"a}rrholm and G{\"o}ran Garellick and Henrik Malchau and M{\"a}kel{\"a}, {Keijo T}",
year = "2016",
month = "12",
doi = "10.1080/17453674.2016.1222804",
language = "English",
volume = "87",
pages = "546--553",
journal = "Acta Orthopaedica (Print Edition)",
issn = "1745-3674",
publisher = "Taylor & Francis",
number = "6",

}

Junnila, M, Laaksonen, I, Eskelinen, A, Pulkkinen, P, Ivar Havelin, L, Furnes, O, Marie Fenstad, A, Pedersen, AB, Overgaard, S, Kärrholm, J, Garellick, G, Malchau, H & Mäkelä, KT 2016, 'Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database', Acta Orthopaedica, bind 87, nr. 6, s. 546-553. https://doi.org/10.1080/17453674.2016.1222804

Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database. / Junnila, Mika; Laaksonen, Inari; Eskelinen, Antti; Pulkkinen, Pekka; Ivar Havelin, Leif; Furnes, Ove; Marie Fenstad, Anne; Pedersen, Alma B; Overgaard, Søren; Kärrholm, Johan; Garellick, Göran; Malchau, Henrik; Mäkelä, Keijo T.

I: Acta Orthopaedica, Bind 87, Nr. 6, 12.2016, s. 546-553.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database

AU - Junnila, Mika

AU - Laaksonen, Inari

AU - Eskelinen, Antti

AU - Pulkkinen, Pekka

AU - Ivar Havelin, Leif

AU - Furnes, Ove

AU - Marie Fenstad, Anne

AU - Pedersen, Alma B

AU - Overgaard, Søren

AU - Kärrholm, Johan

AU - Garellick, Göran

AU - Malchau, Henrik

AU - Mäkelä, Keijo T

PY - 2016/12

Y1 - 2016/12

N2 - Background and purpose - According to previous Nordic Arthroplasty Register Association (NARA) data, the 10-year implant survival of cemented total hip arthroplasties (THAs) is 94% in patients aged 65-74 and 96% in patients aged 75 or more. Here we report a brand-level comparison of cemented THA based on the NARA database, which has not been done previously. Patients and methods - We determined the rate of implant survival of the 9 most common cemented THAs in the NARA database. We used Kaplan-Meier analysis with 95% CI to study implant survival at 10 and 15 years, and Cox multiple regression to assess survival and hazard ratios (HRs), with revision for any reason as endpoint and with adjustment for age, sex, diagnosis, and femoral head material. Results - Spectron EF THA (89.9% (CI: 89.3-90.5)) and Elite THA (89.8% (CI: 89.0-90.6)) had the lowest 10-year survivorship. Lubinus (95.7% survival, CI: 95.5-95.9), MS 30 (96.6%, CI: 95.8-97.4), and C-stem THA (95.8%, CI: 94.8-96.8) had a 10-year survivorship of at least 95%. Lubinus (revision risk (RR) = 0.77, CI: 0.73-0.81), Müller (RR =0.83, CI: 0.70-0.99), MS-30 (RR =0.73, CI: 0.63-0.86), C-stem (RR =0.70, CI: 0.55-0.90), and Exeter Duration THA (RR =0.84, CI: 0.77-0.90) had a lower risk of revision than Charnley THA, the reference implant. Interpretation - The Spectron EF THA and the Elite THA had a lower implant survival than the Charnley, Exeter, and Lubinus THAs. Implant survival of the Müller, MS 30, CPT, and C-stem THAs was above the acceptable limit for 10-year survival.

AB - Background and purpose - According to previous Nordic Arthroplasty Register Association (NARA) data, the 10-year implant survival of cemented total hip arthroplasties (THAs) is 94% in patients aged 65-74 and 96% in patients aged 75 or more. Here we report a brand-level comparison of cemented THA based on the NARA database, which has not been done previously. Patients and methods - We determined the rate of implant survival of the 9 most common cemented THAs in the NARA database. We used Kaplan-Meier analysis with 95% CI to study implant survival at 10 and 15 years, and Cox multiple regression to assess survival and hazard ratios (HRs), with revision for any reason as endpoint and with adjustment for age, sex, diagnosis, and femoral head material. Results - Spectron EF THA (89.9% (CI: 89.3-90.5)) and Elite THA (89.8% (CI: 89.0-90.6)) had the lowest 10-year survivorship. Lubinus (95.7% survival, CI: 95.5-95.9), MS 30 (96.6%, CI: 95.8-97.4), and C-stem THA (95.8%, CI: 94.8-96.8) had a 10-year survivorship of at least 95%. Lubinus (revision risk (RR) = 0.77, CI: 0.73-0.81), Müller (RR =0.83, CI: 0.70-0.99), MS-30 (RR =0.73, CI: 0.63-0.86), C-stem (RR =0.70, CI: 0.55-0.90), and Exeter Duration THA (RR =0.84, CI: 0.77-0.90) had a lower risk of revision than Charnley THA, the reference implant. Interpretation - The Spectron EF THA and the Elite THA had a lower implant survival than the Charnley, Exeter, and Lubinus THAs. Implant survival of the Müller, MS 30, CPT, and C-stem THAs was above the acceptable limit for 10-year survival.

U2 - 10.1080/17453674.2016.1222804

DO - 10.1080/17453674.2016.1222804

M3 - Journal article

C2 - 27550058

VL - 87

SP - 546

EP - 553

JO - Acta Orthopaedica (Print Edition)

JF - Acta Orthopaedica (Print Edition)

SN - 1745-3674

IS - 6

ER -